Open AccessLong‐Term Recovery After Endothelial Colony‐Forming Cells or Human Umbilical Cord Blood Cells Administration in a Rat Model of Neonatal Hypoxic‐Ischemic Encephalopathy
Author(s) -
Grandvuillemin Isabelle,
Garrigue Philippe,
Ramdani Alaa,
Boubred Farid,
Simeoni Umberto,
DignatGeorge Françoise,
Sabatier Florence,
Guillet Benjamin
Publication year - 2017
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.1002/sctm.17-0074
Subject(s) - medicine , umbilical cord , hypoxic ischemic encephalopathy , neuroprotection , encephalopathy , transplantation , cell therapy , stem cell , progenitor cell , cerebral blood flow , pathology , anesthesia , immunology , biology , genetics
Neonatal hypoxic‐ischemic encephalopathy (NHIE) is a dramatic perinatal complication, associated with poor neurological prognosis despite neuroprotection by therapeutic hypothermia, in the absence of an available curative therapy. We evaluated and compared ready‐to‐use human umbilical cord blood cells (HUCBC) and bankable but allogeneic endothelial progenitors (ECFC) as cell therapy candidate for NHIE. We compared benefits of HUCBC and ECFC transplantation 48 hours after injury in male rat NHIE model, based on the Rice‐Vannucci approach. Based on behavioral tests, immune‐histological assessment and metabolic imaging of brain perfusion using single photon emission computed tomography (SPECT), HUCBC, or ECFC administration provided equally early and sustained functional benefits, up to 8 weeks after injury. These results were associated with total normalization of injured hemisphere cerebral blood flow assessed by SPECT/CT imaging. In conclusion, even if ECFC represent an efficient candidate, HUCBC autologous criteria and easier availability make them the ideal candidate for hypoxic‐ischemic cell therapy. S tem C ells T ranslational M edicine 2017;6:1987–1996